Deltex signs on 'significant' new hospital account

Oesophageal doppler monitoring firm Deltex Medical Group announced the addition of a “significant” new hospital account in the US on Tuesday.

The AIM-traded company said the new account is a 600-bed teaching hospital, which initially planned to treat around 40 patients per month within its surgical enhanced recovery programmes.

After the hospital's positive clinical evaluation of ODM was completed in the first half of 2015, implementation was delayed pending a hospital system merger, Deltex explained.

As a result of the combination, there were now 10 further hospitals in the enlarged system.

The procurement agreement covered the whole system, the board confirmed, providing scope for “relatively rapid” conversion of future clinical acceptance of ODM into incremental revenues.

“We are delighted that this new account has now come through the pipeline,” said Deltex Medical chief executive Ewan Phillips.

“It is the sixth major hospital in our Mid-Atlantic sales territory and should further support the growth in one of our top-performing territories, where 2017 first half revenues were over 50% ahead of the first half of 2016.”